



Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting

November 2, 2017

Phase 2 NiCord Data in Allogeneic Bone Marrow Transplant and Preclinical Data for NK Cells to be Presented in Oral Presentations

JERUSALEM, Israel, November 1, 2017 – [Gamida Cell](#), a leading cellular and immune therapeutics company, today announced that two oral presentations on new data from the company's pipeline programs will be presented during the 59th Annual Meeting of the American Society for Hematology (ASH).

The oral presentations will highlight safety and efficacy data for a completed phase 2 study of the company's lead clinical asset, NiCord, as a single cord blood graft, and proof-of-concept data for the advancement of natural killer cells (NK cells) as an immunotherapeutic modality for patients with cancer. These abstracts are now available on the ASH conference [website](#).

Oral Presentations

NiCord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/II Trial

Date & Time: Monday, December 11, 2017 at 4:30 p.m. ET

Session Name: Clinical Allogeneic Transplantation: Results: Donor Selection in the Haplo Transplant Era

Abstract Number: 847

Location: Georgia World Congress Center, Building C, Level 2, Room C202-204

Enhanced In Vivo Persistence and Proliferation of NK Cells Expanded in Culture with the Small Molecule Nicotinamide: Development of a Clinical-Applicable Method for NK Expansion

Date & Time: Monday, December 11, 2017 at 11:00 a.m. ET

Session Name: Cell Collection and Processing: Optimization of Hematopoietic Graft Using Small Molecules in Culture

Abstract Number: 657

Location: Georgia World Congress Center, Building B, Level 2, Room B216-217

About Gamida Cell

Gamida Cell is a leader in cellular and immune therapeutics dedicated to treating patients with cancer and rare genetic diseases. The company is building a diverse pipeline based on its proprietary NAM Technology platform to deliver transformative medicines to patients in need of new treatment options. To learn more about Gamida Cell, including current clinical studies, please visit [gamida-cell.com](#).

Contact:

Katie Engleman

Pure Communications

katie@purecommunications.com

+1 910.509.3977

Investor Contact:

Christina Tartaglia

Stern Investor Relations, Inc.

christina@sternir.com

+ 1 212.362.1200